Sartorius : Proposals of the Supervisory Board to Be Submitted to the Annual General Shareholders’ Meeting of Sartorius AG

• Dividends to rise to 0.51 euros per preference share and 0.50 euros per ordinary share
• Dr. Guido Oelkers to be elected as a representative of shareholders

Göttingen, February 20, 2018 - At today's meeting, the Supervisory Board of Sartorius AG, approved the Executive Board's recommendation to submit a proposal to the Annual General Shareholders' Meeting on April 5, 2018, to raise dividends to 0.51 euros per preference share and 0.50 euros per ordinary share. Prior-year dividends were 0.46 euros and 0.45 euros per preference share and per ordinary share, respectively. Therefore, the total amount disbursed under this proposal would increase by 11.0% to 34.5 million euros from 31.1 million euros a year earlier.

In addition, the Supervisory Board will submit a proposal to the Annual General Shareholders' Meeting to elect Dr. Guido Oelkers to the Supervisory Board as a representative of the shareholders. Guido Oelkers has already been a member of this board since November 2017. He was appointed by court order after Supervisory Board member Professor Arnold Picot, Ph.D., had passed away.

Guido Oelkers, who was born in 1965 and holds a university degree in business administration and economics, has served in various functions in the pharmaceutical and biopharmaceutical sectors since 1987, among these at former Hoechst AG, as well as at Aventis and Nycomed. Since 2017, he has been the President and CEO of Swedish Orphan Biovitrum AB.

This press release contains statements about the future development of the Sartorius Group. The content of these statements cannot be guaranteed as they are based on assumptions and estimates that harbor certain risks and uncertainties. This is a translation of the original German-language press release. Sartorius shall not assume any liability for the correctness of this translation. The original German press release is the legally binding version. Furthermore, Sartorius reserves the right not to be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected.